PACLITAXEL PLUS CARBOPLATIN FOR WOMEN WITH ADVANCED BREAST CANCER

查看全文 作　　者：Ju Liu Qing Li Pin Zhang Jia-yu Wang Long-mei Zhao Bing-he [1]Xu

机构地区：[1]Department of Medical Oncology, Cancer Hospital & Institute, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100021

出　　处：《Chinese Medical Sciences Journal》索引2007年第22卷第2期,共5页

摘　　要：Objective To evaluate the efficacy and safety of combination chemotherapy with paclitaxel and carboplatin for advanced breast cancer (ABC). Methods From January 2001 to March 2006, 45 patients with ABC were treated with combination chemotherapy of paclitaxel and carboplatin. Patients received infusion of paclitaxel 175 mg/m2 on day 1 every 3 weeks or 75 mg/m2 on day 1, 8, 15 every 4 weeks. Carboplatin was administrated on day 2 with a dose of area under the time-concentration curve (AUC) being 5. Results The median number of cycles was 3 (range, 2-6). The overall response rate was 62.2%. Median time to progression was 7.0 months (95%CI:5.1-8.9). Median overall survival was 29.0 months (95%CI: 20.1-37.9). One year survival rate was 73.3%. Response rate for first line and second line treatment were 62.1% and 62.5%, respectively. No significant difference in response existed between visceral metastasis and soft tissue metastasis. The main side effects included nausea/vomiting, neurotoxicity, and hematologic toxicities. Grade Ⅲ to Ⅳ adverse events included nausea/vomiting in 2 cases (4.4%), leukopenia in 17 cases (37.8%), and alopecia in 6 cases (13.3%). Conclusion Combination of paclitaxel and carboplatin is active in treatment of ABC with an acceptable toxicity profile. 关键词：乳腺癌化疗化学药物疗效卡铂紫杉醇

相关文献

参考文献（13）
引证文献（2）
耦合文献（22）

参考文献(13)

引证文献(2)

耦合文献(22)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

PACLITAXEL PLUS CARBOPLATIN FOR WOMEN WITH ADVANCED BREAST CANCER

参考文献(13)

引证文献(2)

耦合文献(22)

用户提示